Scholarlink

<p>The growing burden of insomnia underscores the necessity for accessible and effective treatments, with digital therapeutics offering a promising solution. A systematic search was conducted across seven databases (PubMed, Web of Science, EMBASE, MEDLINE, ProQuest, Scopus, and the Cochrane Library) covering the period from the inception of each database until October 2024. A total of 28 systematic reviews and meta-analyses evaluating digital therapeutics with reported insomnia-related outcomes were included, encompassing 118,970 participants. The primary outcome, Insomnia Severity Index (ISI), indicated that digital therapeutics significantly improved insomnia (SMD = −0.42, <i>p</i> &lt; 0.01), with better results observed during follow-up (SMD = −0.69, <i>p</i> &lt; 0.01). Under the guidance of therapists, digital therapeutics exerted a more positive effect (SMD = −1.05, <i>p</i> &lt; 0.01). The secondary outcomes also showed consistent results, with no significant differences observed in Total Sleep Time (TST) between the post-intervention and follow-up periods. Based on the assessment results, there is sufficient evidence to recommend the use of digital therapeutics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Digital therapeutics for insomnia: an umbrella review and meta-meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月28日

查看全文
  • Can Li,
  • Qiyun Luo,
  • Hong Wu

摘要

The growing burden of insomnia underscores the necessity for accessible and effective treatments, with digital therapeutics offering a promising solution. A systematic search was conducted across seven databases (PubMed, Web of Science, EMBASE, MEDLINE, ProQuest, Scopus, and the Cochrane Library) covering the period from the inception of each database until October 2024. A total of 28 systematic reviews and meta-analyses evaluating digital therapeutics with reported insomnia-related outcomes were included, encompassing 118,970 participants. The primary outcome, Insomnia Severity Index (ISI), indicated that digital therapeutics significantly improved insomnia (SMD = −0.42, p < 0.01), with better results observed during follow-up (SMD = −0.69, p < 0.01). Under the guidance of therapists, digital therapeutics exerted a more positive effect (SMD = −1.05, p < 0.01). The secondary outcomes also showed consistent results, with no significant differences observed in Total Sleep Time (TST) between the post-intervention and follow-up periods. Based on the assessment results, there is sufficient evidence to recommend the use of digital therapeutics.